Objective: No standard chemotherapy has been established yet for large-cell neuroendocrine carcinoma of the lung. Amrubicin is active for both small cell and non-small cell lung cancers, but its activity for large-cell neuroendocrine carcinoma is still unknown. Methods: From January 2002 to December 2009, 18 patients with previously treated advanced large-cell neuroendocrine carcinoma received amrubicin monotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results: The patients comprised 17 males and one female with a median age of 62 years (range, 51 -77). Fourteen and four patients had a performance status of 0 -1 and 2, respectively. Thirteen (72%) patients had received one prior chemotherapy, while the others had received two or more chemotherapies. All the patients had received platinum-based chemotherapy before the amrubicin treatment. A total of 63 cycles of amrubicin chemotherapy was administered in the 18 patients, with a median number of cycles per patient of 2.5 (range, 1 -10). The median dose of amrubicin in the 63 cycles was 40 (range, 30 -45) mg/m 2 /day for 3 days. Grades 3 -4 neutropenia, thrombocytopenia and anemia were seen in 89, 17 and 22% of the patients, respectively. Grade 3 febrile neutropenia occurred in 33% of the patients. Non-hematological toxicity was generally mild and manageable. There were five cases of partial response, six of stable disease and six of progressive disease among the 18 patients, yielding an objective response rate of 27.7%. The median progression-free and overall survivals of the patients were 3.1 and 5.1 months, respectively. Conclusion: Amrubicin was potentially active against previously treated large-cell neuroendocrine carcinoma.
INTRODUCTION
Neuroendocrine tumors of the lung are now classified into four distinct types: typical and atypical carcinoids, which are low-and intermediate-grade tumors, respectively, and largecell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), both of which are high-grade neuroendocrine malignancies. LCNEC came to be recognized as a possibly separate disease entity in the late 1980s (1, 2) , and was established as a distinct pathological entity in 1991 (3) . Pathological diagnosis of LCNEC is based on the neuroendocrine morphology, a large cell size and abundant cytoplasm and evidence of neuroendocrine differentiation detected by immunohistochemistry and/or electron microscopy (3, 4) .
Several studies on surgically resected lung cancer cases suggest an estimated incidence of LCNEC of 3%, and survival after resection of LCNEC seems to be substantially worse than that for other non-SCLCs (NSCLCs), rather resembling that of SCLC (5 -7) . Although establishment of a treatment strategy for unresectable LCNEC is necessary, no standard chemotherapy regimen has been developed, mainly because of the relative infrequency of LCNEC and difficulty # The Author (2011). Published by Oxford University Press. All rights reserved.
Jpn J Clin Oncol 2011;41(7)897-901 doi:10.1093/jjco/hyr065 Advance Access Publication 2 June 2011 in establishing the accurate pathological diagnosis using cytologic and/or small biopsy specimens. Only a few retrospective studies on chemotherapy for unresectable LCNEC have been published. One retrospective case series revealed an objective response rate (ORR) of 50% in 20 patients with advanced LCNEC who received platinum-based chemotherapy (8) . In another report, combinations of platinum and a third-generation anticancer agent yielded an ORR of 59% in 22 chemo-naïve patients with advanced LCNEC (9) . Considering these results, the response of LCNEC to platinum-based chemotherapy may be comparable to that of SCLC and better than that of NSCLC.
Amrubicin, a totally synthetic 9-amino-anthracycline that acts as a potent topoisomerase II inhibitor, has been developed for the treatment of SCLC and NSCLC. In the first-line setting, amrubicin showed an ORR of 76% in patients with SCLC (10), and of 18 -28% in patients with NSCLC (11, 12) . In the second-line setting, amrubicin monotherapy yielded an ORR of 17 -52% in patients with SCLC (13 -15) and of 12% in patients with NSCLC (16) . However, the activity of amrubicin for LCNEC has not yet been described.
In principle, patients with advanced LCNEC are treated with platinum-based chemotherapy in the first-line setting, and with amrubicin monotherapy in the salvage setting at the National Cancer Center Hospital. Thus, we conducted a retrospective review of the data of patients with LCNEC who had received second-or further-line amrubicin treatment, to evaluate the efficacy of this agent against LCNEC.
PATIENTS AND METHODS

PATIENT SELECTION
Patients were retrospectively selected for this study according to the following criteria: (1) a histological or cytological diagnosis of LCNEC; (2) history of one or more prior treatments with chemotherapy; (3) history of single-agent treatment with amrubicin as salvage chemotherapy.
PATHOLOGICAL REVIEW
A pathologist reviewed all the resected, biopsy and/or cytological materials for this study. The pathological diagnosis of LCNEC was established according to the histopathological criteria proposed in the WHO classification. Immunohistochemical and immunocytochemical analyses using a panel of neuroendocrine markers, including chromogranin A, synaptophysin and CD56 (neural cell adhesion molecule) were performed in all patients to confirm the neuroendocrine differentiation of the tumor cells (17) .
DATA COLLECTION AND STATISTICAL ANALYSES
The patients' baseline characteristics, including the age, sex, smoking history and performance status, as well as the data on the clinical disease stage, history of prior therapy, dose of amurubicin, the number of cycles, the tumor responses, toxicity, date of recurrence and the date of the last follow-up were retrospectively obtained from the medical charts. Then, the patients' list was encoded and anonymized. The clinical disease staging was reassessed according to the International Union Against Cancer (UICC) staging criteria, version 7, published in 2009 (18) . The objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumor guideline, version 1.0 (19) . Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0). The overall survival (OS) and progression-free survival (PFS) rates were estimated by the Kaplan -Meier method (20) (Figs 1 and 2) . The OS was measured from the date of the start of amrubicin chemotherapy to the date of death or of the last follow-up. For PFS, documented disease recurrence and death were counted as events. All analyses were performed using the statistical software SPSS (SPSS version 12.0 for Windows; SPSS Inc., Second-line amrubicin for LCNEC Chicago, IL, USA). This study was conducted with the approval of the President of the National Cancer Center Hospital, Tokyo, Japan. The institutional review board and ethical review committee decided to exempt this study from the usual review process, because of its retrospective nature.
RESULTS
Of 24 patients with LCNEC who received salvage chemotherapy from January 2002 to December 2009, 20 (83%) patients received amrubicin and were initially deemed to be eligible for this study. Of these, two patients were excluded after the pathological review, because their final diagnosis was high-grade neuroendocrine malignancy, and therefore, possibly SCLC. Thus, 18 patients were finally included as the subjects of this study. Specimens used for the histological review in these patients were surgically resected specimens in seven patients, surgical biopsy specimens from metastatic sites in five patients, mediastinoscopic biopsy specimens in two patients, CT-guided needle biopsy specimens in two patients and cytologic specimens alone in two patients.
The clinical characteristics of the 18 patients are summarized in Table 1 . The marked predominance of men and smokers in this study was consistent with the demographic features reported from previous studies on LCNEC (6, 7) . Thirteen (72%) patients had received one prior chemotherapy and the others had received two or more chemotherapies. All the patients had received platinum-based chemotherapy before the amrubicin chemotherapy. A combination of cisplatin and irinotecan was the most frequently administered chemotherapeutic regimen prior to the amrubicin therapy.
The starting dose of amrubicin was 45 mg/m 2 /day for 3 days in 4 patients, 40 mg/m 2 /day for 3 days in 13 patients and 35 mg/m 2 /day for 3 days in 1 patient, and the starting dose and dose modification in the subsequent cycles were determined at each physician's discretion. A total of 63 cycles of amrubicin chemotherapy was administered in the 18 patients. The number of chemotherapy cycles was one in five patients, two in four patients, three in one patient, four or more in eight patients and the median number of the cycles per patient was 2.5 (range, 1 -10). The reasons for early discontinuation of chemotherapy after only one cycle were early death in one patient and progressive disease in four patients. The median dose of amrubicin in the 63 cycles was 40 (range, 30 -45) mg/m 2 /day for 3 days. The most frequent toxicity was myelosuppression; Grade 3 or 4 neutropenia, thrombocytopenia and anemia were seen in 89, 17 and 22% of the patients, respectively (Table 2) . Grade 3 febrile neutropenia occurred in 33% of the patients. The non-hematological toxicities were generally mild. Grade 3 infection was noted in one patient (6%), and all other nonhematological toxicities were Grades 1 -2 ( Table 2) . No clear relationship between the starting dose of amrubicin and toxicity was found. One case of sudden death occurred 25 days after the start of administration of amrubicin. This patient had a history of paroxysmal atrial fibrillation, but no history of other cardiac diseases, cerebrovascular diseases or venous thromboembolism. He had been well until the bedtime on the 25th day of chemotherapy, when he suddenly complained of dyspnea. About 30 min later, he was found to be in a state of cardiopulmonary arrest upon arrival at an emergency hospital. Autopsy was not done. A causal relationship of this event to amrubicin administration was unassessable.
One patient was not evaluable for the tumor response due to early death. There were five cases of partial response, six of stable disease and six of progressive disease among the 18 patients, yielding an ORR of 27.7% [95% confidence interval (CI): 9.7 -53.5%]. Three partial responses were obtained in the 13 patients who had received only one previous chemotherapy, and two partial responses were obtained among the remaining five patients who had received two or more previous chemotherapies. The median PFS and OS of all the patients were 3.1 (CI: 0.9 -5.7) months and 5.1 (CI: 2.2-9.7) months, respectively (Figs 1 and 2) .
DISCUSSION
This study showed that amrubicin monotherapy yielded an ORR of 27.7% and median OS of 5.1 months in patients with LCNEC who had previously received treatment with platinum-based chemotherapy. These figures are comparable to those reported for amrubicin chemotherapy for SCLC in the second-line setting; the reported ranges of the ORR and the median OS in previous Phase II studies are 17 -52% and 6.0 -11.6 months, respectively (13 -15) . In the patients with pretreated NSCLC, amrubicin monotherapy yielded an ORR of 12% and OS of 8.5 months, respectively (16) . Although directly comparable historical control data were not available, the assumption of efficacy of amrubicin in this study seems to be reasonable, considering that amrubicin monotherapy is known to be potentially active against previously treated LCNEC. Toxicities observed in this study were mainly hematological, similar to previous reports of amrubicin chemotherapy. Although Grades 3 -4 neutropenia was noted in 89% of the patients and Grade 3 febrile neutropenia in 33%, the adverse effects were manageable in all the cases by careful monitoring of myelosuppression and appropriate dose reduction of amrubicin. The median age of this study, 62 years, sounds younger when compared with a median age of lung cancer in Japan. It may be possible to employ 40 mg/m 2 of amrubicin only in the young LCNEC patients (70 years or less) with a good performance status.
It has been difficult to conduct clinical trials for LCNEC patients because of the relatively rare occurrence of this disease and the difficulty in accurate pathological diagnosis of unresectable LCNEC. A Phase II trial to evaluate the efficacy and safety of irinotecan and cisplatin in chemo-naive patients with advanced LCNEC is ongoing in Japan. Further clinical studies to investigate effective second-line chemotherapy for LCNEC patients are also required. Considering the results of this study, amrubicin appears to be one of the promising candidate treatments that needs to be evaluated in future clinical trials for pretreated LCNEC patients.
In conclusion, amrubicin was potentially active against previously treated LCNEC, with acceptable toxicities. Second-line amrubicin for LCNEC
